Implantable glucose sensor company Senseonics has launched a remote monitoring app for its users in Europe, the Middle East, and Africa, where its CGM system is distributed by Roche. The app, called ...
Implantable CGM company Senseonics has received approval from the FDA for the non-adjunctive indication for its Eversense device. Senseonics is only the third company to secure this indication, which ...
The Middle East and Africa Continuous Glucose Monitoring (CGM) market is set for growth, driven by increasing diabetes rates, technological advancements, and healthcare awareness. Projected to rise ...
Ascensia Diabetes Care and Senseonics are stepping up promotion of their continuous glucose monitor (CGM) with a campaign designed to lure people away from the market leaders Abbott and Dexcom. The ...
Germantown, Md.-based Senseonics Holdings Inc. (NYSE-MKT:SENS) is touting positive results from a study of its Eversense implantable continuous glucose monitoring (CGM) system, reporting that the ...
With a single sensor, the Eversense 365 system provides one year of use, versus 10-14 days with short-term CGM’s for minimal life disruption “The approval of Eversense 365 represents a significant ...
The next-generation CGM is now available in Sweden, with launches expected in Germany, Spain and Italy during the coming weeks as part of a phased roll out Eversense 365 doubles sensor lifespan from ...
Senseonics has received FDA clearance for a 365-day continuous glucose monitor (CGM). The Germantown, MD-based company said Eversense 365 is the first year-long CGM system, designed to minimize the ...
(MENAFN- GlobeNewsWire - Nasdaq) The Middle East and Africa Continuous Glucose Monitoring (CGM) market is set for growth, driven by increasing diabetes rates, technological advancements, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results